Given the important role of TLR4 in different kinds of preclinical AKI models, the inhibition of TLR4 and its downstream effectors can serve as the novel therapeutic target for treatment of CI−AKI through preventing renal inflammation and subsequent kidney damage. This evidence concerns the gene TLR4 and acute kidney injury.